HCW Biologics Inc. financial data

Symbol
HCWB on Nasdaq
Industry
Pharmaceutical Preparations
Location
2929 N Commerce Pkwy, Miramar, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 144 % -87.7%
Debt-to-equity 79.6 % +316%
Return On Equity -147 % -225%
Return On Assets -81.7 % -116%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8M shares +5.4%
Entity Public Float 42.8M USD -2.95%
Common Stock, Value, Issued 3.78K USD +5.38%
Weighted Average Number of Shares Outstanding, Basic 37.2M shares +3.73%
Weighted Average Number of Shares Outstanding, Diluted 37.2M shares +3.73%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 2.76M USD -2.57%
Research and Development Expense 7.54M USD -23.1%
General and Administrative Expense 16.2M USD +69.6%
Operating Income (Loss) -27.9M USD -50.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25M USD -67.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.4M USD -52.9%
Earnings Per Share, Basic -0.76 USD/shares -52%
Earnings Per Share, Diluted -0.76 USD/shares -52%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.08M USD -77.8%
Other Assets, Current 187K USD -40.9%
Assets, Current 6.21M USD -79.3%
Property, Plant and Equipment, Net 22.6M USD +92.4%
Operating Lease, Right-of-Use Asset 28.1K USD -85.3%
Other Assets, Noncurrent 28.5K USD -88.8%
Assets 30.4M USD -30.1%
Accounts Payable, Current 10.5M USD +801%
Liabilities, Current 13.4M USD +197%
Deferred Income Tax Liabilities, Net 147K USD
Operating Lease, Liability, Noncurrent 7.48K USD -94.6%
Liabilities 21.7M USD +98.7%
Retained Earnings (Accumulated Deficit) -78M USD -54.1%
Stockholders' Equity Attributable to Parent 8.74M USD -73.2%
Liabilities and Equity 30.4M USD -30.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.6M USD +0.94%
Net Cash Provided by (Used in) Financing Activities 4.22M USD +222023%
Net Cash Provided by (Used in) Investing Activities -130K USD +56.8%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 37.8M shares +5.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 489K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.08M USD -77.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.4M USD +58.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Cash and Cash Equivalents, Period Increase (Decrease) 6.39M USD
Deferred Tax Assets, Gross 18.5M USD +59.8%
Operating Lease, Liability 153K USD -50%
Depreciation 795K USD +34.8%
Payments to Acquire Property, Plant, and Equipment 130K USD -56.8%
Property, Plant and Equipment, Gross 23.5M USD +80.1%
Operating Lease, Liability, Current 28.1K USD -84.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.7K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 28.8K USD -31.9%
Additional Paid in Capital 86.7M USD +4.22%
Depreciation, Depletion and Amortization 244K USD -18.5%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 28.7K USD -83.3%
Operating Leases, Future Minimum Payments Due 28.7K USD -85.7%
Interest Expense 190K USD -13.9%